PT2399 was validated in vivo, showing activity in both tumor cell lines and patient-derived xenografts, in both treatment-naïve and Sunitinib-resistant tumors, and was associated with a reduction in the levels of circulating EPO, a target of HIF2A in blood [19]. This evidence concerns the gene EPAS1 and neoplasm.